NFKB1 and ovarian cancer: The differential subcellular expression of COMMD1 in ovarian cancer, together with the notion that nuclear COMMD1 inhibits NF-κB and HIF activity and that COMMD1 might have a function in DNA damage response prompted us to evaluate whether nuclear COMMD1 affects the sensitivity of ovarian cancer cells to cisplatin [3,10].